HOOKIPA Pharma Receives FDA Clearance of its IND Application for HB-700 for the Treatment of KRAS-Mutated Cancers

DENVER, Colo., Apr 24, 2024 (247marketnews.com)- HOOKIPA Pharma Inc. (NASDAQ:HOOK) received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for HB-700, for the treatment of KRAS-mutated cancers, triggering a final $10 million milestone payment from Roche.

“We are proud to have another IND cleared for a potentially powerful oncology program. Our HB-700 program targets five KRAS-mutations found in multiple cancer indications with a single product candidate,” commented Joern Aldag, Chief Executive Officer at HOOKIPA. “Importantly, the submission of the IND results in us receiving a final $10 million milestone payment. We continue to define our clinical development strategy which includes the possibility of collaboration or partnership for this program.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://www.247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
[email protected]

Related news for (NASDAQ:HOOK)

    NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.